Share this Page:
A recent study published in Clinical Cancer Research analysed tumour tissue samples obtained in a clinical trial to investigate how the expression of the PD-L1 receptor on the tumour cells influenced outcomes in patients with metastatic renal cell carcinoma (RCC) receiving targeted therapy.
Positive expression of the PD-L1 receptor on RCC tumour cells was associated with shorter progression-free and overall survival compared with negative tumour cell PD-L1 expression when patients were treated with cabozantinib, everolimus or suntinib.
In conclusion, higher PD-L1 expression on RCC tumour cells was associated with inferior clinical outcomes among patients with metastatic RCC treated with targeted therapy.
